TOMZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TOMZ is not a good buy right now. The technical trend is bearish, near-term pattern odds skew negative (expected drift lower over day/week/month), fundamentals in the latest quarter weakened materially, and there are no fresh catalysts or proprietary buy signals to justify an impatient entry.
Price/Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5, indicating the stock remains in a downtrend across long-, mid-, and short-term horizons. Momentum: MACD histogram is negative (-0.00219) and still below zero (bearish), though contracting slightly (selling pressure easing but not reversed). RSI(6) ~47.9 is neutral—no oversold bounce signal. Levels: Pivot ~0.743 with post-market ~0.7398 (slightly below pivot). Immediate support S1 ~0.71 then S2 ~0.69. Resistance R1 ~0.775 then R2 ~0.795. With price below pivot and trend bearish, upside attempts likely face supply at ~0.775/0.795. Pattern-based forecast: Similar-pattern analysis implies a 60% probability of further downside (-0.58% next day, -1.17% next week, -3.85% next month), reinforcing a poor near-term entry for an impatient buyer.
Intellectia Proprietary Trading Signals
No news in the last week (no identified event-driven catalysts). MACD bearish momentum is negatively contracting, which can sometimes precede stabilization, but this is not a confirmed reversal signal.
Technical downtrend (bearish moving-average stack) with price slightly below pivot and no proprietary buy signals. Statistical forward-bias from similar patterns points to further declines over the next day/week/month. No recent news catalysts to change the narrative. Trading trends show hedge funds and insiders as Neutral (no supportive accumulation signal).
Latest reported quarter: 2025/Q3. Revenue fell to $2.01M (-20.88% YoY). Net income worsened to -$0.45M (down -863.79% YoY), indicating a sharp deterioration in profitability. EPS was -0.02 (flat YoY by the provided measure), and gross margin slipped to 57.83% (-1.41% YoY). Overall: weakening top-line and meaningfully worse earnings trajectory—unfavorable for a near-term buy case.
No analyst rating/price target change data provided, so no clear Wall Street pro-vs-con consensus can be inferred from this dataset. (Also, no recent congress trading data available, and no politician/influential-figure transactions were provided.)
